1-3 of 3
Maria T. Kuipers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Free
Marie José Kersten, Kirsten Saevels, Evelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, Claire Vennin, Eva Santermans, Anna D. D. van Muyden, Jeevan Shetty, Esmée P. Hoefsmit, Omotayo Fasan, Maria T. Kuipers, Sébastien Anguille, Joost S.P. Vermaat
Journal: Blood
Blood (2024) 144 (Supplement 1): 93.
https://doi.org/10.1182/blood-2024-205360
Published: 2024
Journal Articles

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Free
Janneke W. de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G.N.J. Mutsaers, Anne G.H. Niezink, Jaap A. van Doesum, Yasmina I.M. Serroukh, Louise W. Muntendam, Astrid E. Pulles, Esther J. Kret, Aniko Sijs-Szabo, Jesse Oomen, Astrid M.P. Demandt, Wendy B.C. Stevens, Maria T. Kuipers, Elise R.A. Pennings, Anne M. Spanjaart, Marie José Kersten, Margot Jak, Lisanne V. van Dijk, Marjolein W.M. van der Poel, Joost S.P. Vermaat, Tom van Meerten
Journal: Blood
Blood (2024) 144 (Supplement 1): 1747.
https://doi.org/10.1182/blood-2024-209879
Published: 2024
Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Free
Marie José Kersten, Kirsten Saevels, Yves Beguin, Joost S.P Vermaat, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille
Journal: Blood
Blood (2023) 142 (Supplement 1): 2113.
https://doi.org/10.1182/blood-2023-172736
Published: 2023